Research Article

New Enhancement beyond Radiation Field Improves Survival Prediction in Patients with Post-Treatment High-Grade Glioma

Tao Yuan, Xiaoli Ji, Yawu Liu, Guodong Gao, Jia-Liang Ren, Deyou Huang, and Guanmin Quan

1Department of Medical Imaging, The Second Hospital of Hebei Medical University, Shijiazhuang, China
2Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland
3GE Healthcare China, Beijing, China
4Department of Radiology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China

Correspondence should be addressed to Guanmin Quan; quanguanmin@163.com

Received 1 June 2020; Accepted 29 April 2021; Published 6 May 2021

The imaging signs which can accurately predict survival prognosis after standard treatment of high-grade glioma (HGG) are highly desirable. This study aims to explore the role of new enhancement beyond radiation field (NERF) in the survival prediction in patients with post-treatment HGG. The present study included 142 pathologically confirmed HGG patients who had received standard treatment. NERF, as well as other conventional MR findings and clinical variables, were included in univariate and multivariate analyses for evaluating their impacts on progression-free survival (PFS) and overall survival (OS). Univariate analysis showed that histological grade \( p < 0.008 \) and NERF \( p < 0.001 \) were the prognostic variables for poor PFS, whereas histological grade \( p = 0.017 \), NERF \( p = 0.001 \), and new subventricular zone enhancement (nSVZE) \( p = 0.001 \) were prognostic variables for poor OS. The multivariate analysis showed that NERF (HR 3.93; 95% CI 1.93–8.01; \( p = 0.001 \)) and nSVZE (HR 3.92; 95% CI 1.95–7.89; \( p = 0.001 \)) were the prognostic variables for poor OS. However, only nSVZE was (HR 3.29; 95% CI 2.04–5.28; \( p = 0.001 \)) the prognostic variable for poor PFS. When combining the NERF with the clinical and other MR variables, the highest AUC (0.924) and specificity (0.899) for predicting poor OS were achieved. The location of new developed enhancements relevant to high dose radiation field appears to be the main determinant of their prognostic value. Our results suggest that the new enhancement beyond radiation field can improve the survival prediction in patients with HGG after standard treatment.

1. Introduction

High-grade gliomas (HGGs) remain a challenging disease in neuro-oncology. HGGs are the most common malignant and rapid-growing tumors [1]. In spite of standard treatment, including gross-total resection, concurrent radiation therapy, and chemotherapy, the overall 5-year survival remains relatively low [2–4]. Therefore, the method, especially the noninvasive imaging techniques, which can accurately predict disease progression after standard treatment is highly desirable so that the salvage therapy, such as reradiation, could be triggered and the patients’ progression-free interval time may consequently be prolonged [5].

At present, conventional magnetic resonance (MR) imaging, including T2-weighted imaging (T2WI), fluid-attenuated inversion recovery sequence (FLAIR), and contrast-enhanced T1-weighted imaging (CE-T1WI), is still the preferred imaging method for evaluating glioma patients after treatment [6, 7]. In the response assessment in neuro-oncology (RANO) criteria, CE-T1WI is the most important sequence in evaluation of response and tumor progression in the HGG patients [8]. After standard treatment, the newly appeared enhancement and its size are important factors in estimating the recurrence and prognosis, but the location of the new enhancement is less studied [9]. The new enhancement, which can situate within or beyond the radiation
field, is usually caused by tissue response to the surgical trauma, necrosis, and, importantly, tumor recurrence and radiation damage. The new enhancing lesions, especially those located beyond radiation field, would be the sign of tumor progression. Therefore, these new enhancing lesions probably influence the survival outcome of the patients with post-treatment HGG.

As the new enhancement beyond radiation field (NERF) may be caused by tumor recurrence, we deduced that the new enhancing lesions could influence the survival outcome. Therefore, the purpose of this retrospective study was to explore the value of NERF by combining it with other MR features and clinical variables in survival prediction in the patients with post-treatment HGG.

2. Materials and Methods

2.1. Patients. We identified consecutive 167 brain HGG patients who had received standard treatment according to National Comprehensive Cancer Network (NCCN) guideline [9] between October 2016 and October 2018. All these patients received tumor gross-total resection, radiation therapy, and chemotherapy (CCRT) after surgery and six cycles of adjuvant temozolomide (TMZ).

The inclusion criteria included the following: (1) the diagnosis confirmed by histopathologic examination; (2) gross-total resection of HGG; (3) with age older than 18 years; (4) having undergone serial MR scans: after resection and before and after CCRT. The patients had successfully undergone at least 3 times post-CCRT MR scans; (5) with follow-up for more than 12 months. The treatment response was defined based on the RANO criteria [7]. We collected the following data, including patients’ demographics, pathologic diagnosis, treatment schedule, MR imaging data, and clinical outcomes. The median follow-up span was 24 months (range 21–28). Due to the retrospective nature, the written informed consent was waived. According to RANO criteria, disease progression is defined as presence of newly enhancing lesions of enlargement of preexisting enhancing lesions on CE-T1WI MR series in addition to T2/FLAIR imaging [4]. Progression-free survival (PFS) was defined as the date of surgery to the date of progression or the date of the last follow-up without progression [10]. Overall survival (OS) was defined from the date of surgery to the date of the last follow-up or death [11].

2.2. Imaging Data. All subjects underwent 3.0T MR scan (Philips MRI Systems Achieva, Netherlands). The imaging protocol included pre- and postcontrast CE-T1WI, and T2WI/FLAIR. The CE-T1WI was performed after Gd-DTPA (0.1 mmol per kilogram of body weight of gadobutrol, Gadovist, Bayer Schering Pharma, Berlin, Germany) which was injected at a rate of 3 ml/sec, followed by a 20 ml 0.9% saline flush using the same flow rate. 58 patients underwent dynamic susceptibility contrast (DSC) perfusion MRI with perfusion-weighted gradient-echo echo-planar sequence. Relative cerebral blood volume (rCBV) of new enhancing lesions was calculated when compared to that of the mirror cerebral region.

2.3. Imaging Analysis. We reviewed all the follow-up MR data in Picture Archiving and Communication System (PACS). The new enhancing lesions included (1) NERF, which located beyond radiation field, and (2) new subventricular zone enhancement (nSVZE). The enhancement patterns of residual cavity wall included (1) thin-linear enhancement (partial or entire wall enhancement with thickness < 3 mm), (2) thick-linear enhancement (partial or entire wall enhancement of 3–5 mm in thickness), and (3) nodular wall enhancement (with nodular enhancement of 5–10 mm in thickness) [12]. Since thin-linear enhancement might be reactive enhancement and thick-linear/nodular enhancement might be tumor remnant and the microscopic infiltration of tumor cells [11, 12], we categorized the residual cavity wall enhancement into two groups: no enhancement and thin-linear enhancement and thick-linear/nodular enhancement. The MR imaging findings were identified independently by two neuroradiologists (with 5- and 20-year experiences in diagnostic radiology). When a disagreement existed, a consent was reached after consulting another neuroradiologist (with 25-year experiences in diagnostic radiology).

2.4. Statistical Analysis. All statistical analyses were performed with SPSS 21.0 for Windows (SPSS Inc., Chicago, IL, USA). The quantitative data were described as mean and standard deviation when they were in normal distribution and as median and quartile, when they were in nonnormal distribution. Categorical variables were analyzed with log-rank test. Cox’s proportional hazards model was used for multivariate analysis. Receiver operating characteristic (ROC) curve analysis was employed in determining threshold value, accuracy, sensitivity, and specificity in differentiating poor and good outcomes. A p value < 0.05 was regarded as statistically significant. The interobserver consistency between the two neuroradiologists was evaluated with intraclass correlation coefficient (ICC). The survival times were estimated with the Kaplan–Meier methods.

3. Results

3.1. Baseline Characteristics. Twenty-five of 167 patients were excluded for the followed reasons: (1) only biopsy was made (n = 3); (2) with age < 18 years (n = 3); (3) lost to follow-up during the first 12 months after gross-total resection (n = 9); (4) poor quality of MR images (n = 10). Thus, 142 patients were enrolled in this study, with a mean age of 47.4 ± 14.50 years (range 18–73 years). The subjects included 79 male and 63 female patients. The pathological analysis showed that the HGGs were WHO grade III (n = 78) and grade IV (n = 64).

All patients completed the standard treatment according to the NCCN guideline. The demographics, radiation dose, pathologic characteristics, and imaging features on conventional MRI, as well as clinical outcome are listed in Table 1. The median PFS was 11.50 months (95% confidence interval (CI) 12.73–17.93 months) and median OS was 18.00 months (95% CI 18.70–24.00 months) (Figures 1(a) and
Table 1: Baseline characteristics of HGG patients \( (n = 142) \).

| Characteristics                                        | Mean/median (standard deviation/95% CI), \( n \) (%) |
|--------------------------------------------------------|-----------------------------------------------------|
| Age (years)                                            | 47.47 (14.35)                                       |
| Radiation dose (Gy)                                    | 58.92 (5.91)                                        |
| PFS (months)                                           | 345 (382–538)                                       |
| OS (months)                                            | 540 (561–720)                                       |
| Gender                                                 |                                                    |
| Female                                                 | 63 (44.37%)                                         |
| Male                                                   | 79 (55.63%)                                         |
| IDH \( (N = 64) \)                                     |                                                    |
| Wild                                                   | 45 (69.35%)                                         |
| Mutation                                               | 19 (30.65%)                                         |
| Histopathology                                         |                                                    |
| Anaplastic oligodendroglioma                           | 43 (30.28%)                                         |
| Anaplastic astrocytoma                                 | 30 (21.13%)                                         |
| Anaplastic pleomorphic xanthoastrocytoma                | 5 (3.52%)                                           |
| Glioblastoma                                           | 64 (45.07%)                                         |
| Nonenhanced T2/FLAIR hyperintensity lesions            |                                                    |
| Stable or decrease                                     | 80 (54.93%)                                         |
| Increase                                               | 62 (45.07%)                                         |
| Enhancement of residual cavity wall                    |                                                    |
| Nonenhancement or thin-linear enhancement               | 64 (45.07%)                                         |
| Thick-linear or nodular enhancement                    | 78 (54.93%)                                         |
| PWI \( (N = 58) \)                                     |                                                    |
| Progress                                               | 47 (81.03%)                                         |
| Stable                                                 | 11 (18.97%)                                         |
| NERF                                                   |                                                    |
| Negative                                               | 70 (49.30%)                                         |
| Positive                                               | 72 (50.70%)                                         |
| nSVZE                                                  |                                                    |
| Negative                                               | 65 (45.77%)                                         |
| Positive                                               | 77 (54.26%)                                         |
| Outcome                                                |                                                    |
| Remain alive till due time                             | 90 (63.38%)                                         |
| Dead                                                   | 52 (36.62%)                                         |

HGG, high-grade glioma; CI, confidence interval; PFS, progression-free survival; OS, overall survival; IDH, isocitrate dehydrogenase; FLAIR, fluid-attenuated inversion recovery; NERF, new enhancement beyond the radiation field; nSVZE, new subventricular zone enhancement.

Figure 1: Kaplan–Meier survival curves for PFS (a) and OS (b) according to NERF. NERF, new enhancement beyond the radiation field; PFS, progression-free survival; OS, overall survival.
1(b). 52 patients (36.62%) were dead during the follow-up period.

10 of 23 patients in this series underwent MGMT testing which showed positive MGMT methylation, including 7 patients with NERF lesion and 3 patients without NERF lesions ($p = 0.363$). 64 patients underwent IDH genetic testing. But we had not found significant difference between patients with NERF lesion and patients without NERF lesions ($p = 0.130$).

In the follow-up MR images, NERF was found in 72 patients, nSVZE in 77 patients, thick-linear and nodular wall enhancement in 78 patients, and nonenhancement hyper-intensity on T2WI/FLAIR images in 64 patients. Higher rCBV (1.27; 95% CI 0.538–1.64) was found in 47 of 58 patients who underwent DSC-PWI, including 28 patients with shorter OS and 19 with longer OS ($p = 0.063$).

142 HGG patients included the following histological types: 43 patients with anaplastic oligodendroglioma, 30 with anaplastic astrocytoma, 5 with anaplastic pleomorphic xanthoastrocytoma, and 64 with glioblastoma. In terms of new enhancing lesions, there was no significant difference about the incidence of new enhancement beyond radiation field (NERF) between high-grade astrocytoma (56.25%) and high-grade oligodendroglioma (64.28%) patients ($p = 0.492$).

### 3.2. Univariate and Multivariate Analyses

Univariate analysis showed that histological grade ($p = 0.008$) and NERF ($p = 0.001$) were the prognostic variables for poor PFS, whereas histological grade ($p = 0.017$), NERF ($p = 0.001$), and nSVZE ($p < 0.001$) were prognostic variables for poor OS. The incidence of nSVZE in patients with shorter OS (68.18%, 60/88) was higher than that in patients with longer OS (31.48%, 17/54) ($p < 0.001$). The multivariate analysis (Table 2), NERF (HR 3.93; 95% CI 1.93–8.01; $p < 0.001$), and nSVZE (HR 3.92; 95% CI 1.95–7.89; $p < 0.001$) were confirmed as the prognostic variables for poor OS. However, only nSVZE was (HR 3.29; 95% CI 2.04–5.28; $p < 0.001$) the prognostic variable for poor PFS.

### 3.3. Diagnostic Efficiency of Survival State

The agreement was excellent between the two neuroradiologists for evaluation of nonenhancing T2/FLAIR lesions (ICC 0.931; 95% CI 0.904–0.951; $p < 0.001$), enhancement pattern of residual cavity wall (ICC 0.932; 95% CI 0.905–0.951; $p < 0.001$), NERF (ICC 0.949; 95% CI 0.930–0.964; $p < 0.001$), and nSVZE (ICC 0.951; 95% CI 0.931–0.965; $p < 0.001$).

The ROC analysis showed that combination of clinical factors, including age and histologic grade, achieved AUC 0.879 for predicting poor OS with a sensitivity of 0.865, specificity of 0.744, and Youden index of 0.6108. The diagnostic performance for poor OS was improved when adding conventional MRI factors, including nonenhanced T2/FLAIR hyperintensity lesions and enhancement of residual cavity wall, with AUC of 0.901, sensitivity 0.788, specificity 0.833, and Youden index of 0.625. Interestingly, when we added NERF to combination model, which including clinical and conventional MRI factors, the AUC was 0.924, with a sensitivity of 0.788, specificity of 0.889, and Youden index of 0.677 in predicting poor OS (Table 3, Figure 2).

Figures 3–5 show the classic examples of patients with NERF, without new enhancing lesion, and with nSVZE.

### 4. Discussion

Predicting the outcome of post-treatment HGG is critical for individualized management. Our study is to evaluate the effect of the location of new enhancement relative to radiation field in discriminating favorable and unfavorable survival prognosis in HGG patients after standard treatment. Our results showed that the new enhancement beyond radiation field, namely, NERF, can be used to improve the accuracy in predicting outcome in those postoperative HGG patients, particularly, when NERF was added to the predicting model.

CE-T1WI is routinely used and is the most important MR sequence in the evaluation of post-treatment HGG patients. In clinical practice, only the increase of enhancement lesions size is considered as an imaging marker of tumor progression according to RANO criteria [4, 8]. The new enhancement could appear in the residual cavity wall and resection area, as well as in the regions which are outside the radiation field. The causes of these new enhancing lesions include both progressive disease and treatment necrosis [13, 14]. We categorized the new enhancement into NERF and nSVZE. The definition of new enhancement in the subventricular zone had been used in recent years in other literatures [5]. However, as far as we know, it is first time to offer the definition of NERF. There are several possible explanations for the NERF, including residual tumor, tumor recurrence, and treatment necrosis. In this study, all the patients underwent gross-total resection of HGG. In the follow-up MR scan at one month after operation, the normal tissue response to the surgical trauma could present as thin-linear enhancement on the residual cavity wall. On the other hand, the residual tumor may lead to thick-linear or nodular enhancement shortly after operation. Thus, CE-T1WI may help for detecting the lesions originated from residual tumor lesions. Moreover, the NERF lesions may come from those so-called tumor stem cells, which can migrate over long distance from the subventricular region and lead to new enhanced lesions [15]. In this series, NERF lesions were found in 58 of 88 patients (65.91%) with shorter OS. In contrast, there was a lower incidence (25.93%, 14/54) of NERF lesions for those patients with longer OS ($p < 0.001$). We may estimate that tumor recurrence which originated from microresidual tumor cells would be the most common cause of NERF lesions and lead to unfavorable outcome.

Our data also showed that nSVZE was a risk factor for a poor outcome. It is interesting that both univariate and multivariate analyses indicated the nSVZE, contact to subventricular zone, which was a strong prognostic variable for both PFS and OS. In our study, 44 of 77 patients with nSVZE had unfavorable survival outcome. Previous studies have shown there is a correlation between preoperative invasion at the subventricular zone and the unfavorable outcome of grade IV gliomas, suggesting an unfavorable
The subventricular zone, which is believed to be a pool of stem cells and is within 5 mm to the ventricular wall, may be a structure that the brain tumor stem cells would be derived from [5]. Several studies have shown that aggressive gliomas may be related to the recurrence of neuronal stem-like cells in the subventricular zone [5, 17–19]. When we reviewed the preoperational MRI data, we did not find enhancing lesion contacted to ventricular wall. Thus, we speculated that the nSVZEs in our study were related to the recruitment of those so-called neuronal stem cells. These cells were infititive to proliferate and could be resistant to standard chemo- and radiotherapy [15]. The salvage radiotherapy with high dose per fraction might even stimulate glioma cell migration [5]. The resistance to the standard and salvage therapies may be the cause of unfavorable PFS and OS ≥ 660 days; poor prognosis, OS < 660 days; β, regression coefficient; OR, odds ratio; FLAIR, fluid-attenuated inversion recovery; NERF, new enhancement beyond the radiation field; nSVZE, new subventricular zone enhancement.

| Characteristics                  | Favorable prognosis | Poor prognosis         |
|----------------------------------|---------------------|------------------------|
|                                   | β       | OR (95%CI) | p value | β       | OR (95%CI) | p value |
| Histological grade               | 1.262   | 3.533 (0.217, 46.143) | 0.336 | −0.923 | 0.397 (0.132, 1.198) | 0.101 |
| NERF                             | −2.535  | 0.079 (0.006, 1.052)  | 0.055 | −1.802 | 0.165 (0.0.045, 0.605) | 0.007 |
| nSVZE                            | −0.07   | 0.468 (0.094, 2.328)  | 0.353 | −0.541 | 0.582 (0.167, 2.026) | 0.395 |

OS, overall survival; favorable prognosis, OS ≥ 660 days; poor prognosis, OS < 660 days; β, regression coefficient; OR, odds ratio; FLAIR, fluid-attenuated inversion recovery; NERF, new enhancement beyond the radiation field; nSVZE, new subventricular zone enhancement.

Figure 2: Comparison of ROC curve analyses for different combinations of clinical and MR variables for predicting poor OS. The combination of Clin + Conven MRI + NERF presents the high diagnostic performance (AUC 0.924; 95% CI 0.881, 0.967), with significant level of p < 0.001 to any other combinations. ROC, receiver operating characteristic; AUC, area under ROC curve; Clin = age + histological grade; Conven MRI = nonenhanced T2/FLAIR hyperintensity lesions + enhancement of residual cavity wall; NERF, new enhancement beyond the radiation field.

Table 3: ROC curve analyses of diagnostic performance of combinations of various variables.

| Characteristics                  | AUC     | 95% CI       | Sensitivity | Specificity | Youden index | p value |
|----------------------------------|---------|--------------|-------------|-------------|--------------|---------|
| Clin                             | 0.879   | (0.825, 0.933) | 0.865       | 0.744       | 0.610        | < 0.001 |
| Clin + Conven MRI               | 0.901   | (0.851, 0.950) | 0.788       | 0.833       | 0.625        | < 0.001 |
| Clin + Conven MRI + NERF        | 0.924   | (0.881, 0.967) | 0.788       | 0.889       | 0.677        | < 0.001 |

ROC, receiver operating characteristic; AUC, area under ROC curve; Clin = age + histological grade; Conven MRI = nonenhanced T2/FLAIR hyperintensity lesions + enhancement of residual cavity wall; NERF, new enhancement beyond the radiation field.
OS in the patients with nSVZE. However, on the other hand, the subventricular zone (SVZ) is significantly more susceptible to radiation damage and this has been well reported. This radiation damage in SVZ includes demyelination, disruption of microvascular structure, and secondary local inflammation. The alteration of SVZ microenvironment would evoke new enhancement in CE-T1WI. Thus, if the new enhancing lesion in SVZ is encountered, its location should be noted relevant to radiation field instead of SVZ.

There are several limitations in this study. First, as a retrospective analysis, only patients with grade III and IV gliomas were enrolled, thus may have a selection bias. In the future, we should include grade II gliomas with wild-type isocitrate dehydrogenase (IDH), which are associated with increased risk of aggressive disease; these grade II gliomas can be defined as so-called “molecular glioblastoma” [20]. The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy working committee suggested that histologic grade II and III IDH-wild-type astrocytic glioma should be referred as diffuse astrocytic glioma, IDH-wild-type, for these gliomas containing high-level EGFR amplification or TERT promoter mutations [21]. Second, molecular pathology is an important factor in predicting outcome, including...
mutation of IDH, O6-methylguanine-DNA methyltransferase (MGMT), and 1p19q co-deletion. The molecular pathology has not been widely included in routine clinical examination, especially in the era before 2016. Since only 23 and 64 patients underwent MGMT and IDH genetic testing separately and no significant difference was found between patients with NERF and those without NERF in our series, we did not analyze the role of biology of HGG in survival prediction. Further analysis should be made for new enhancing lesions based on genetics of HGG in the future. Finally, several other prognostic factors, including relative cerebral blood volume, diffusion characteristics, enhancement lesion size, and salvage therapy, were not included. Although PWI is valuable for differentiation true progression from false progression in post-treatment HGG patients, we had not found significant difference of relative cerebral blood volume (rCBV) between patients with shorter OS and patients with longer OS. Thus, PWI factors were not enrolled in multivariate analysis of survival state.

In conclusion, our data showed that the new enhancing lesion is a useful imaging marker in survival prediction in the HGG patients after standard treatment. The patients with NERF on CE-T1WI after standard therapy may need aggressive and salvage treatments. As CE-T1WI is a convenient, noninvasive, and useful method for evaluating HGG after treatment and the new enhancement can be easily evaluated, further longitudinal studies are needed to confirm our findings, especially the impact of the NERF lesions on survival outcome in the recurrent HGG patients who receive salvage therapy.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

TY, XJ, DH, J-LR, and GQ made a substantial contribution to the concept and design, acquisition of data or analysis, and interpretation of data; GQ, XJ, and TY drafted the article and revised it critically for relevant intellectual content; GQ, GG, XJ, and DH performed MR examination and follow-up of patients; all the authors approved the final version of the manuscript. Tao Yuan and Xiaoli Ji are co-first authors and contributed equally to this study.

Acknowledgments

This study was supported by the Specialist Leadership Project of Hebei Province (no. 361004, GQ), Technology Tracking Program for Medical Application of Hebei Province (no. G201725, GQ), and The Health and Family Planning Commission of Guangxi Zhuang Autonomous Region (no. Z2016425, DH).

References

[1] G. Reifenberger, H.-G. Wirsching, C. B. Knobbe-Thomsen, and M. Weller, “Advances in the molecular genetics of gliomas - implications for classification and therapy,” Nature Reviews Clinical Oncology, vol. 14, no. 7, pp. 434–452, 2017.
[2] M. D. Sørensen, R. H. Dahlrot, H. B. Boldt et al., “Tumor-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumor subtype,” Neuropathology and Applied Neurobiology, vol. 44, no. 2, pp. 1–37, 2017.
[3] R. Stupp, W. P. Mason, M. J. van den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for...
glioblastoma,” *New England Journal of Medicine*, vol. 9, no. 2, pp. 196–197, 2005.

[4] T. H. Ung, D. E. Ney, D. Damek et al., “The neurologic assessment in neuro-oncology (NANO) scale as an assessment tool for survival in patients with primary glioblastoma,” *Neurosurgery*, vol. 84, no. 3, pp. 1–9, 2018.

[5] J. Attal, L. Chaltiel, V. Lubrano et al., “Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation,” *Journal of Neuro-Oncology*, vol. 136, no. 2, pp. 413–419, 2017.

[6] H. Zhou, K. Chang, H. X. Bai et al., “Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas,” *Journal of Neuro-Oncology*, vol. 142, no. 2, pp. 299–307, 2019.

[7] S. C. Eisele, P. Y. Wen, and E. Q. Lee, “Assessment of brain tumor response: RANO and its offspring,” *Current Treatment Options in Oncology*, vol. 17, no. 7, pp. 35–47, 2016.

[8] A. Berberich, T. Hielscher, P. Kickingereder et al., “Non-measurable speckled contrast-enhancing lesions appearing during course of disease are associated with IDH mutation in high-grade astrocytoma patients,” *International Journal of Radiation Oncology*Biology*Physics*, vol. 102, no. 5, pp. 1472–1480, 2018.

[9] R. Swarm, A. Pickar, A. Angelescu et al., “NCCN clinical practice guidelines in oncology™,” *JNCCN*, vol. 8, pp. 1046–1086, 2006.

[10] K. Han, M. Ren, W. Wick et al., “Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials,” *Neuro-Oncology*, vol. 16, no. 5, pp. 696–706, 2013.

[11] C. Majos, M. Cos, S. Castañer et al., “Early post-operative magnetic resonance imaging in glioblastoma: correlation among radiological findings and overall survival in 60 patients,” *European Radiology*, vol. 26, no. 4, pp. 1048–1055, 2016.

[12] B. R. Kim, S. H. Choi, T. J. Yun et al., “MR imaging analysis of non-measurable enhancing lesions newly appearing after concomitant chemoradiotherapy in glioblastoma patients for prognosis prediction,” *PLoS One*, vol. 11, no. 11, Article ID e0166096, 2016.

[13] M. Voss, K. Franz, J. P. Steinbach et al., “Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients,” *Journal Of Neuro-Oncology*, vol. 142, no. 1, pp. 161–169, 2019.

[14] S. F. Winter, F. Loebel, J. Loeffler et al., “Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology,” *Neuro-Oncology*, vol. 21, no. 9, pp. 1118–1130, 2019.

[15] C. Altmann, S. Keller, and M. H. H. Schmidt, “The role of SVZ stem cells in glioblastoma,” *Cancers*, vol. 11, no. 4, pp. 448–471, 2019.

[16] B. Wen, F. Fu, L. Hu, Q. Cai, and J. Xie, “Subventricular zone predicts high velocity of tumor expansion and poor clinical outcome in patients with low grade astrocytoma,” *Clinical Neurology and Neurosurgery*, vol. 168, no. 3, pp. 12–17, 2018.

[17] A. M. Mistry, P. D. Kelly, J.-N. Gallant et al., “Comparative analysis of subventricular zone glioblastoma contact and ventricular entry during resection in predicting dissemination, hydrocephalus, and survival,” *Neurosurgery*, vol. 85, no. 5, pp. E924–E932, 2019.

[18] T. H.-K. Liang, S.-H. Kuo, C.-W. Wang et al., “Adverse prognosis and distinct progression patterns after concurrent chemoradiotherapy for glioblastoma with synchronous subventricular zone and corpus callosum invasion,” *Radiotherapy and Oncology*, vol. 118, no. 1, pp. 16–23, 2016.

[19] K. L. Chaichana, M. J. Mcgirt, J. Frazier, F. Attenello, H. Guerrero-Cazares, and A. Quinones-Hinojosa, “Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection,” *Journal of Neuro-Oncology*, vol. 89, no. 2, pp. 219–224, 2008.

[20] Y. Michiwaki, N. Hata, M. Mizoguchi et al., “Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification,” *Clinical Neurology and Neurosurgery*, vol. 187, Article ID 105556, 2019.

[21] D. J. Brat, K. Aldape, H. Colman et al., “cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”” *Acta Neuropathologica*, vol. 136, no. 5, pp. 805–810, 2018.